The oncogenic miR-429 promotes triple-negative breast cancer progression by degrading DLC1

Lines of evidence have demonstrated that the oncogenic miRNAs are pivotal to the progression of breast cancer. In this study, we investigated the biological traits of microRNA-429 (miR-429) in triple-negative breast cancer (TNBC) and the underlying molecular mechanism. We found that miR-429 was nota...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yao, Meng, Xue, Luo, Yuqing, Luo, Shuai, Li, Jin, Zeng, Jiafei, Huang, Xiang, Wang, Jinjing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564445/
https://www.ncbi.nlm.nih.gov/pubmed/37737712
http://dx.doi.org/10.18632/aging.205051
_version_ 1785118500692426752
author Li, Yao
Meng, Xue
Luo, Yuqing
Luo, Shuai
Li, Jin
Zeng, Jiafei
Huang, Xiang
Wang, Jinjing
author_facet Li, Yao
Meng, Xue
Luo, Yuqing
Luo, Shuai
Li, Jin
Zeng, Jiafei
Huang, Xiang
Wang, Jinjing
author_sort Li, Yao
collection PubMed
description Lines of evidence have demonstrated that the oncogenic miRNAs are pivotal to the progression of breast cancer. In this study, we investigated the biological traits of microRNA-429 (miR-429) in triple-negative breast cancer (TNBC) and the underlying molecular mechanism. We found that miR-429 was notably overexpressed in TNBC, and promoted TNBC cell proliferation, migration, and invasion by degrading the tumor suppressor DLC1. In conclusion, our findings reveal the mechanism of tumorigenic miR-429 in TNBC, which paves the way for target therapies translation in clinical settings.
format Online
Article
Text
id pubmed-10564445
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Impact Journals
record_format MEDLINE/PubMed
spelling pubmed-105644452023-10-11 The oncogenic miR-429 promotes triple-negative breast cancer progression by degrading DLC1 Li, Yao Meng, Xue Luo, Yuqing Luo, Shuai Li, Jin Zeng, Jiafei Huang, Xiang Wang, Jinjing Aging (Albany NY) Research Paper Lines of evidence have demonstrated that the oncogenic miRNAs are pivotal to the progression of breast cancer. In this study, we investigated the biological traits of microRNA-429 (miR-429) in triple-negative breast cancer (TNBC) and the underlying molecular mechanism. We found that miR-429 was notably overexpressed in TNBC, and promoted TNBC cell proliferation, migration, and invasion by degrading the tumor suppressor DLC1. In conclusion, our findings reveal the mechanism of tumorigenic miR-429 in TNBC, which paves the way for target therapies translation in clinical settings. Impact Journals 2023-09-21 /pmc/articles/PMC10564445/ /pubmed/37737712 http://dx.doi.org/10.18632/aging.205051 Text en Copyright: © 2023 Li et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Li, Yao
Meng, Xue
Luo, Yuqing
Luo, Shuai
Li, Jin
Zeng, Jiafei
Huang, Xiang
Wang, Jinjing
The oncogenic miR-429 promotes triple-negative breast cancer progression by degrading DLC1
title The oncogenic miR-429 promotes triple-negative breast cancer progression by degrading DLC1
title_full The oncogenic miR-429 promotes triple-negative breast cancer progression by degrading DLC1
title_fullStr The oncogenic miR-429 promotes triple-negative breast cancer progression by degrading DLC1
title_full_unstemmed The oncogenic miR-429 promotes triple-negative breast cancer progression by degrading DLC1
title_short The oncogenic miR-429 promotes triple-negative breast cancer progression by degrading DLC1
title_sort oncogenic mir-429 promotes triple-negative breast cancer progression by degrading dlc1
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564445/
https://www.ncbi.nlm.nih.gov/pubmed/37737712
http://dx.doi.org/10.18632/aging.205051
work_keys_str_mv AT liyao theoncogenicmir429promotestriplenegativebreastcancerprogressionbydegradingdlc1
AT mengxue theoncogenicmir429promotestriplenegativebreastcancerprogressionbydegradingdlc1
AT luoyuqing theoncogenicmir429promotestriplenegativebreastcancerprogressionbydegradingdlc1
AT luoshuai theoncogenicmir429promotestriplenegativebreastcancerprogressionbydegradingdlc1
AT lijin theoncogenicmir429promotestriplenegativebreastcancerprogressionbydegradingdlc1
AT zengjiafei theoncogenicmir429promotestriplenegativebreastcancerprogressionbydegradingdlc1
AT huangxiang theoncogenicmir429promotestriplenegativebreastcancerprogressionbydegradingdlc1
AT wangjinjing theoncogenicmir429promotestriplenegativebreastcancerprogressionbydegradingdlc1
AT liyao oncogenicmir429promotestriplenegativebreastcancerprogressionbydegradingdlc1
AT mengxue oncogenicmir429promotestriplenegativebreastcancerprogressionbydegradingdlc1
AT luoyuqing oncogenicmir429promotestriplenegativebreastcancerprogressionbydegradingdlc1
AT luoshuai oncogenicmir429promotestriplenegativebreastcancerprogressionbydegradingdlc1
AT lijin oncogenicmir429promotestriplenegativebreastcancerprogressionbydegradingdlc1
AT zengjiafei oncogenicmir429promotestriplenegativebreastcancerprogressionbydegradingdlc1
AT huangxiang oncogenicmir429promotestriplenegativebreastcancerprogressionbydegradingdlc1
AT wangjinjing oncogenicmir429promotestriplenegativebreastcancerprogressionbydegradingdlc1

Ejemplares similares